AS
ASBP.US Aspire BioPharma, Inc.
- Market cap
- USD 11.8M
- P/E
- -
- P/B
- 1.00x
- ROE
- -76.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ASBP.US undervalued?
Graham numberThe Graham number of Aspire BioPharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aspire BioPharma, Inc. fundamental analysis
No fundamental analysis for Aspire BioPharma, Inc. yet.
Aspire BioPharma, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aspire BioPharma, Inc.
Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems. The company develops a nano-technology-based sublingual drug delivery system designed to enhance the pharmacokinetic performance of active pharmaceutical ingredients, supplements, and nutraceuticals to increase bioavailability, improve speed of onset, and reduce side effects. Its lead prescription product candidate, Sublingual High Dose Aspi…
Full company profileAspire BioPharma, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aspire BioPharma, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 6.20K | 183K |
| Gross Profit | - | 0.00 | 0.00 | 0.00 | -116.00 | 36.1K |
| Operating Income | -25.5K | -976K | -1.34M | -1.21M | -19.4M | -8.19M |
| EBITDA | 2.32K | -976K | 5.81M | -1.21M | -11.3M | -5.02M |
| Net Income | -25.5K | 3.34M | 4.46M | -1.31M | -24.5M | -8.98M |
| EPS | -0.04 | 3.72 | 9.31 | -34 | -16 | -8.65 |
| Balance Sheet | ||||||
| Total Assets | 293K | 300M | 20.0M | 148K | 1.31M | 13.5M |
| Total Liabilities | 294K | 11.1M | 403K | 1.69M | 7.69M | 1.78M |
| Shareholders' Equity | -475.00 | 289M | 19.6M | -1.54M | -6.38M | 11.8M |
| Cash & Short-term Investments | - | 497K | 11.2K | 3.63K | 1.00M | 12.2M |
| Total Debt | 239K | 28.0K | 12.4K | 1.27M | 1.38M | - |
| Cash Flow | ||||||
| Operating Cash Flow | -260.00 | -143K | -653K | -265K | -4.92M | -10.3M |
| Capital Expenditure | 0.00 | 4.90M | 3.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -260.00 | -5.04M | -653K | -265K | -4.92M | -10.3M |
| Ratios | ||||||
| ROE | - | 1.2% | 22.8% | - | - | -76.4% |
| ROA | -8.7% | 1.1% | 22.3% | -885.1% | -1,865.7% | -66.3% |
| Net Profit Margin | - | - | - | - | -394,725.1% | -4,910.6% |
| Debt to Equity | - | 0.00x | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aspire BioPharma, Inc. dividends
Aspire BioPharma, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:40 on Jan 16, 2026.
Who owns Aspire BioPharma, Inc.
- Insiders 26.63%
- Institutions 7.86%
- Public & others 65.51%
- Shares outstanding 1.40M
- Free float 1.10M
Top funds holding ASBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 8.78K | 0.63% | -0.37% | Sep 2026 |
| Fidelity Series Total Market Index | 2.46K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.75K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 1.07K | 0.08% | 0.00% | Aug 2026 |
Top institutions holding ASBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 14.8K | 1.06% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 10.5K | 0.75% | +624.34% | Jun 2026 |
| Vanguard Capital Management, LLC | 10.4K | 0.74% | +3,872.52% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 10.1K | 0.72% | +10,511.58% | Jun 2026 |
| Crewe Advisors LLC | 677.00 | 0.05% | -0.15% | Jun 2026 |
| Tower Research Capital LLC | 283.00 | 0.02% | +293.06% | Jun 2026 |
| The Toronto-Dominion Bank | 166.00 | 0.01% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 3.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 1.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 1.00 | 0.00% | -99.98% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 0.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Efficient Wealth Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | 0.00% | Jun 2026 |
Aspire BioPharma, Inc. company profile
- Company name
- Aspire BioPharma, Inc.
- Ticker
- ASBP.US
- Exchange
- USA Stocks
- Listed since
- Apr 11, 2022
- Sector
- Consumer Cyclical
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 23150 Fashion Drive, Estero, FL, United States, 33928
- Phone
- (415) 592-7399
- Website
- aspirelakewoodholdings.com
About Aspire BioPharma, Inc.
Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems. The company develops a nano-technology-based sublingual drug delivery system designed to enhance the pharmacokinetic performance of active pharmaceutical ingredients, supplements, and nutraceuticals to increase bioavailability, improve speed of onset, and reduce side effects. Its lead prescription product candidate, Sublingual High Dose Aspirin, targets pain management and anti-inflammatory applications. The company also develops Alprazolam in a sublingual formulation for anxiety treatment and offers Buzz Bomb Caffeine, a sublingually administered caffeine pre-workout consumer supplement. Additionally, it develops sublingual formulations of Melatonin for sleep aid, Sublingual ED for erectile dysfunction, testosterone products, and vitamins D, E, and K. The company targets therapeutic applications including heart attack and stroke, anxiety, antiplatelet conditions, nausea, pain management, and inflammation. The company also designs and manufactures engineered control systems that integrate mechanical engineering, electronics, and computer science for body, chassis, powertrain, electrical, and interior vehicle applications. It offers HMI and actuation systems, safety systems, shift systems, pedal systems, park systems, mechanical control cables, and mechatronic systems. Aspire-Lakewood Holdings, Inc. was formerly known as Aspire Biopharma Holdings, Inc. and changed its name to Aspire-Lakewood Holdings, Inc. in September 2026. Aspire-Lakewood Holdings, Inc. was incorporated in 2021 and is based in Estero, Florida.
Aspire BioPharma, Inc. management
3- Mr. Kraig T. HigginsonInterim CEO, President & Executive Chairman of the Board · born 1956
- Mr. Ernest J. Scheidemann Jr.Chief Financial Officer · born 1961
- Mr. Stephen E. QuesenberryGeneral Counsel & Corporate Secretary · born 1963